SCRIBE THERAPEUTICS
Live / Applied — Fifth extension granted (statement of use) (as of 15 Dec 2025)
What this means for you
Not registered yet, but its 20 May 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97420511
- Mark type
- Stylized text
- Filed
- 20 May 2022
- Published for opposition
- 25 Apr 2023
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer
- Class 042 — Scientific and technological services: Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, and therapeutic products and services; Design and development of engineered cells for use in scientific research and in drug discovery and development; Providing medical and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; Molecular diagnostic services in the nature of genetic testing for medical research purposes
Owner
- Scribe Therapeutics Inc., Alameda, CA, US
- Scribe Therapeutics Inc., Alameda, CA, US
Prosecution history
- 15 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Dec 2025 — SOU EXTENSION 5 GRANTED
- 14 Dec 2025 — SOU EXTENSION 5 FILED
- 14 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 09 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Dec 2025 — SOU EXTENSION 4 GRANTED
- 18 Jun 2025 — SOU EXTENSION 4 FILED
- 09 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Dec 2024 — SOU EXTENSION 3 GRANTED
- 15 Dec 2024 — SOU EXTENSION 3 FILED
- 15 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jun 2024 — SOU EXTENSION 2 GRANTED